Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion.
Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months.
Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 +/- 0.63 (P < 0.0001) units to 0.64 +/- 0.6 units for the 2.5-mg group (P < 0.0001). In the 1.25-mg group, 26 (68%) eyes gained > or =3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost > or =3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved > or =3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost > or =3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 +/- 140 microm to 244 +/- 125 microm (P < 0.0001) versus 444 +/- 175 microm to 234 +/- 80 microm in the 2.5-mg group (P < 0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported.
Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0b013e3181bcef53 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment.
Pharmaceutics
January 2025
Centre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen's University Belfast, Belfast BT7 1NN, UK.
Background/objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated.
Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA.
Advancing Insights into Pediatric Macular Diseases: A Comprehensive Review.
J Clin Med
January 2025
Department of Ophthalmology, Boston Children's Hospital, Boston, MA 02115, USA.
Pediatric macular disorders are a diverse group of inherited retinal diseases characterized by central vision loss due to dysfunction and degeneration of the macula, the region of the retina responsible for high-acuity vision. Common disorders in this category include Stargardt disease, Best vitelliform macular dystrophy, and X-linked retinoschisis. These conditions often manifest during childhood or adolescence, with symptoms such as progressive central vision loss, photophobia, and difficulty with fine visual tasks.
View Article and Find Full Text PDFCombined Multilayered Amniotic Membrane Graft and Fibrin Glue as a Surgical Management of Limbal Dermoid Cyst.
J Clin Med
January 2025
Ophthalmology Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
To report the cosmetic, clinical, and visual outcomes of a combined surgical approach for treating a corneal/limbal dermoid using excision and a three-layered amniotic membrane graft with fibrin glue. An 18-year-old female presented with impaired vision and ocular discomfort caused by a prominent dome-shaped limbal congenital dermoid on the inferotemporal cornea, resulting in a significant aesthetic concern. A full assessment, including refraction, best-corrected visual acuity (BCVA), corneal topography, aberrometry and anterior segment OCT (AS-OCT) was conducted to plan the surgical approach.
View Article and Find Full Text PDFDNA Methyltransferase Expression (DNMT1, DNMT3a, and DNMT3b) as a Potential Biomarker in Age-Related Macular Degeneration.
J Clin Med
January 2025
H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, 1990096 Lisbon, Portugal.
Age-related macular degeneration (AMD) is a global cause of vision loss, with limited therapeutic options highlighting the need for effective biomarkers. This study aimed to characterize plasma DNA methyltransferase expression (, , and ) in AMD patients and explore divergent expression patterns across different stages of AMD. : Thirty-eight AMD patients were prospectively enrolled and stratified by disease severity: eAMD, iAMD, nAMD, and aAMD.
View Article and Find Full Text PDFAcceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections.
J Clin Med
January 2025
Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland.
Age-related macular degeneration (AMD) is a progressive, chronic eye disease with no permanent cure currently available. Symptoms of the disease, including distorted and blurred vision and gradual loss of central vision, significantly aggravate patients' daily functioning. The purpose of this study was to assess the acceptance of the disease among patients diagnosed with neovascular age-related macular degeneration before treatment and after receiving seven intravitreal injections and to determine how it was related to the values of visual parameters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!